Hetero
Biosimilar developer, India. 5 development products across 5 molecules: adalimumab, bevacizumab, darbepoetin alfa, denosumab, rituximab.
About Hetero
Hetero holds Indian permissions for five biosimilar molecules: darbepoetin, bevacizumab, rituximab, adalimumab and denosumab. Its adalimumab, Mabura, was permitted in 2017 with a full set of uses, and its denosumab is the only Indian product permitted first for the cancer dose. All of its biosimilars are Indian products.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | Mabura | · | · | · | · | · | Jul 2017 | · | 1/7 |
| Bevacizumab | Hetero bevacizumab | · | · | · | · | · | May 2016 | · | 1/7 |
| Darbepoetin alfa | Hetero darbepoetin alfa | · | · | · | · | · | Jan 2014 | · | 1/7 |
| Denosumab | Hetero denosumab | · | · | · | · | · | Dec 2024 | · | 1/7 |
| Rituximab | Hetero rituximab | · | · | · | · | · | Mar 2015 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Hetero, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOJan 2014Hetero Drugs (INN only), darbepoetin alfa
- CDSCOMar 2015Hetero Drugs (INN only), rituximab
- CDSCOMay 2016Hetero Drugs (INN only), bevacizumab
- CDSCOJul 2017Mabura, adalimumab
- CDSCODec 2024Hetero Biopharma (INN only), denosumab
Compare Hetero with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant